Holen Sie sich die Stockscreener-App
9.87
1.07%
0.09
Schlusskurs vom Vortag:
$9.78
Offen:
$9.72
24-Stunden-Volumen:
6,268
Relative Volume:
0.06
Marktkapitalisierung:
$142.31M
Einnahmen:
$166.88M
Nettoeinkommen (Verlust:
$-74.18M
KGV:
-1.9467
EPS:
-5.07
Netto-Cashflow:
$1.14M
1W Leistung:
-1.25%
1M Leistung:
+5.16%
6M Leistung:
-31.97%
1J Leistung:
-42.23%
1-Tages-Spanne:
$9.72
$9.88
1-Wochen-Bereich:
$9.585
$10.17
52-Wochen-Spanne:
$7.8701
$18.37
Anika Therapeutics Inc Stock (ANIK) Company Profile
Firmenname
Anika Therapeutics Inc
Sektor
Telefon
(781) 457-9000
Adresse
32 WIGGINS AVENUE, BEDFORD, MA
Vergleichen Sie ANIK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
9.87 | 141.01M | 166.88M | -74.18M | 1.14M | -5.07 |
|
ZTS
Zoetis Inc
|
142.84 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.41 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.2433 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.09 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
447.64 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-17 | Eingeleitet | B. Riley Securities | Buy |
| 2024-11-01 | Bestätigt | Barrington Research | Outperform |
| 2023-08-14 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2023-03-07 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2022-11-09 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2022-10-14 | Fortgesetzt | Stephens | Equal-Weight |
| 2022-03-09 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2022-03-09 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2021-11-16 | Eingeleitet | Stephens | Overweight |
| 2021-07-16 | Eingeleitet | UBS | Neutral |
| 2020-12-16 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2020-05-08 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-01-21 | Hochstufung | Sidoti | Neutral → Buy |
| 2020-01-10 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2019-11-05 | Eingeleitet | BWS Financial | Sell |
| 2019-09-24 | Bestätigt | Barrington Research | Outperform |
| 2019-09-23 | Herabstufung | First Analysis Sec | Strong Buy → Outperform |
| 2019-07-25 | Hochstufung | First Analysis Sec | Neutral → Strong Buy |
| 2019-02-22 | Herabstufung | First Analysis Sec | Outperform → Neutral |
| 2019-02-22 | Herabstufung | Sidoti | Buy → Neutral |
| 2018-07-27 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2018-06-20 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2018-06-20 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2018-05-04 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2018-02-23 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2018-01-24 | Hochstufung | First Analysis Sec | Equal-Weight → Overweight |
| 2017-10-27 | Bestätigt | Barrington Research | Outperform |
| 2016-05-09 | Hochstufung | Singular Research | BUY - Long-Term → Buy |
| 2016-04-27 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2016-02-26 | Bestätigt | Barrington Research | Outperform |
Alle ansehen
Anika Therapeutics Inc Aktie (ANIK) Neueste Nachrichten
What is the fair value estimate for Anika Therapeutics Inc. (AKP) stock in 20252025 EndofYear Setup & Technical Pattern Based Signals - newser.com
What dividend safety rating applies to Anika Therapeutics Inc. (AKP) stockTrade Ideas & Scalable Portfolio Growth Methods - newser.com
Is Anika Therapeutics Inc. stock supported by strong cash flows2025 Winners & Losers & Weekly Setup with High ROI Potential - newser.com
Why Anika Therapeutics Inc. stock could rally in 2025Weekly Profit Analysis & Breakout Confirmation Alerts - newser.com
Does Anika Therapeutics Inc. show high probability of reboundJuly 2025 EndofMonth & Safe Entry Trade Reports - newser.com
Detecting support and resistance levels for Anika Therapeutics Inc.Sell Signal & Safe Entry Point Identification - newser.com
Is Anika Therapeutics Inc. stock positioned for long term growthTrade Ideas & Risk Managed Investment Entry Signals - newser.com
Strategies to average down on Anika Therapeutics Inc.2025 Year in Review & Free High Accuracy Swing Entry Alerts - newser.com
Key metrics from Anika Therapeutics Inc.’s quarterly data2025 Retail Activity & Low Risk Entry Point Tips - newser.com
Why Anika Therapeutics Inc. stock could outperform in 20252025 Support & Resistance & Free Fast Gain Swing Trade Alerts - newser.com
How to escape a deep drawdown in Anika Therapeutics Inc.2025 Growth vs Value & Smart Allocation Stock Reports - newser.com
Anika Therapeutics, Inc. (NASDAQ:ANIK) is a favorite amongst institutional investors who own 60% - Yahoo Finance
Using AI based signals to follow Anika Therapeutics Inc.Quarterly Investment Review & Stepwise Entry/Exit Trade Alerts - newser.com
Can Anika Therapeutics Inc. stock sustain revenue growth2025 Momentum Check & Real-Time Price Movement Reports - Fundação Cultural do Pará
Will Anika Therapeutics Inc. (AKP) stock benefit from sector leadershipMarket Performance Report & Daily Technical Forecast Reports - Fundação Cultural do Pará
Can Anika Therapeutics Inc. stock attract ESG capital inflowsJuly 2025 Macro Moves & Fast Gain Swing Alerts - Fundação Cultural do Pará
Is Anika Therapeutics Inc. stock attractive for growth ETFsWeekly Gains Summary & Long-Term Safe Investment Ideas - Fundação Cultural do Pará
Anika Therapeutics’ Integrity Implant System Study: A Market Game Changer? - TipRanks
Finanzdaten der Anika Therapeutics Inc-Aktie (ANIK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Anika Therapeutics Inc-Aktie (ANIK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Nunes Anne | SVP, Chief Operations Officer |
Mar 17 '25 |
Option Exercise |
0.00 |
3,637 |
0 |
21,722 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 17 '25 |
Option Exercise |
0.00 |
6,448 |
0 |
49,847 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 17 '25 |
Option Exercise |
0.00 |
25,132 |
0 |
209,472 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 11 '25 |
Option Exercise |
0.00 |
2,561 |
0 |
18,837 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 11 '25 |
Option Exercise |
0.00 |
7,663 |
0 |
45,649 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 11 '25 |
Option Exercise |
0.00 |
30,060 |
0 |
197,015 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
3,296 |
0 |
17,235 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 10 '25 |
Option Exercise |
0.00 |
5,465 |
0 |
39,590 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 10 '25 |
Option Exercise |
0.00 |
20,002 |
0 |
172,826 |
6.10%
1.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):